Literature DB >> 9632571

Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.

R K Gupta1, D N Taylor, D A Bryla, J B Robbins, S C Szu.   

Abstract

Conjugate vaccines were prepared by binding hydrazine-treated lipopolysaccharide (DeALPS) from Vibrio cholerae O1, serotype Inaba, to cholera toxin (CT) variants CT-1 and CT-2. Volunteers (n = 75) were injected with either 25 microg of DeALPS, alone or as a conjugate, or the licensed cellular vaccine containing 4 x 10(9) organisms each of serotypes Inaba and Ogawa per ml. No serious adverse reactions were observed. DeALPS alone did not elicit serum LPS or vibriocidal antibodies in mice and only low levels of immunoglobulin M (IgM) anti-LPS in the volunteers. Recipients of the cellular vaccine had the highest IgM anti-LPS levels, but the difference was not statistically significant from that elicited by the conjugates. The conjugates elicited the highest levels of IgG anti-LPS (DeALPS-CT-2 > DeALPS-CT-1 > cellular vaccine). Both conjugates and the cellular vaccine elicited vibriocidal antibodies: after 8 months, recipients of cellular vaccine had the highest geometric mean titer (1,249), followed by DeALPS-CT-2 (588) and DeALPS-CT-1 (330). The correlation coefficient between IgG anti-LPS and 2-mercaptoethanol (2-ME)-resistant vibriocidal antibodies was 0. 81 (P = 0.0004). Convalescent sera from cholera patients had a mean vibriocidal titer of 2,525 that was removed by treatment with 2-ME. The vibriocidal activities of sera from all vaccine groups and from the patients were absorbed (>75%) by LPS but not by either CT-1 or CT-2. Conjugate-induced IgG vibriocidal antibodies persisted longer than those elicited by the whole-cell vaccine. Both conjugates, but not the cellular vaccine, elicited IgG anti-CT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632571      PMCID: PMC108318     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera.

Authors:  J D Clemens; F van Loon; D A Sack; J Chakraborty; M R Rao; F Ahmed; J R Harris; M R Khan; M Yunus; S Huda
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests.

Authors:  W H Mosley; W E Woodward; K M Aziz; A S Rahman; A K Chowdhury; A Ahmed; J C Feeley
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

3.  Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.

Authors:  R I Glass; A M Svennerholm; M R Khan; S Huda; M I Huq; J Holmgren
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

4.  Kinetics of the vibriocidal antibody response to live oral cholera vaccines.

Authors:  S S Wasserman; G A Losonsky; F Noriega; C O Tacket; E Castañeda; M M Levine
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

5.  Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects.

Authors:  A DeMaria; M A Johns; H Berberich; W R McCabe
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

6.  Identification of a novel sugar, 4-amino-4,6-dideoxy-2-O-methylmannose in the lipopolysaccharide of Vibrio cholerae O1 serotype Ogawa.

Authors:  T Ito; T Higuchi; M Hirobe; K Hiramatsu; T Yokota
Journal:  Carbohydr Res       Date:  1994-03-18       Impact factor: 2.104

7.  Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.

Authors:  M L Clements; M M Levine; C R Young; R E Black; Y L Lim; R M Robins-Browne; J P Craig
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

8.  Serological Properties of gammaG and gammaM Antibodies to the Somatic Antigen of Vibrio cholerae During the Course of Immunization of Rabbits.

Authors:  R M Pike; C H Chandler
Journal:  Infect Immun       Date:  1971-06       Impact factor: 3.441

9.  Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; W H Mosley
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

10.  Immunological differences among the cholera/coli family of enterotoxins.

Authors:  B A Marchlewicz; R A Finkelstein
Journal:  Diagn Microbiol Infect Dis       Date:  1983-06       Impact factor: 2.803

View more
  17 in total

Review 1.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

2.  Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.

Authors:  Peter Ftacek; Victor Nelson; Shousun C Szu
Journal:  Glycoconj J       Date:  2013-08-17       Impact factor: 2.916

3.  Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Rina Saksena; Alaullah Sheikh; Mohammad Murshid Alam; Firdausi Qadri; Stephen B Calderwood; Pavol Kovác; Edward T Ryan
Journal:  Vaccine       Date:  2009-06-27       Impact factor: 3.641

4.  Immunological properties of complex conjugates based on Vibrio cholerae O1 Ogawa lipopolysaccharide antigen.

Authors:  E Paulovicová; E Machová; A Hostacká; S Bystrický
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 5.  Carbohydrate vaccines: developing sweet solutions to sticky situations?

Authors:  Rena D Astronomo; Dennis R Burton
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

6.  Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid.

Authors:  A Boutonnier; S Villeneuve; F Nato; B Dassy; J M Fournier
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

8.  Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.

Authors:  Z Kossaczka; J Shiloach; V Johnson; D N Taylor; R A Finkelstein; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

9.  Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes.

Authors:  Madushini N Dharmasena; Shelly J Krebs; Ronald K Taylor
Journal:  Microbiology (Reading)       Date:  2009-04-23       Impact factor: 2.777

10.  Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Gil Ben-Menachem; Vince Pozsgay; John B Robbins; Rachel Schneerson
Journal:  Vaccine       Date:  2008-05-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.